Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data

Trial StartBBT001Positive

AI Analysis

Summary

Bambusa Therapeutics initiated subcutaneous dosing of BBT001, a long-acting bispecific antibody targeting IL-4Rα and IL-31, in atopic dermatitis patients following positive intravenous proof-of-concept data. The company is expanding global development of the candidate with a high-concentration subcutaneous formulation.

Clinical Trial Data

Outcome Details

First patient dosed in subcutaneous dosing study following positive intravenous proof-of-concept data

Importance:6/10

Sentiment:

0.70

bispecific antibodyIL-4RαIL-31subcutaneous formulationatopic dermatitisclinical development

Related Companies

$GBCMD $TRAX $RTSL

Read the original article

Published by PR Newswire Biotech on October 1, 2026 1:00 PM

Read Original